ATE171472T1 - Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4 - Google Patents
Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4Info
- Publication number
- ATE171472T1 ATE171472T1 AT93905927T AT93905927T ATE171472T1 AT E171472 T1 ATE171472 T1 AT E171472T1 AT 93905927 T AT93905927 T AT 93905927T AT 93905927 T AT93905927 T AT 93905927T AT E171472 T1 ATE171472 T1 AT E171472T1
- Authority
- AT
- Austria
- Prior art keywords
- human interleukin
- pct
- monoclonal antibodies
- cloning
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84165992A | 1992-02-19 | 1992-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE171472T1 true ATE171472T1 (de) | 1998-10-15 |
Family
ID=25285411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93905927T ATE171472T1 (de) | 1992-02-19 | 1993-02-18 | Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4 |
Country Status (18)
Country | Link |
---|---|
US (2) | US5863537A (de) |
EP (1) | EP0627002B1 (de) |
JP (1) | JPH07502901A (de) |
KR (1) | KR0158240B1 (de) |
CN (1) | CN1076966A (de) |
AT (1) | ATE171472T1 (de) |
AU (1) | AU684041B2 (de) |
CA (1) | CA2130436C (de) |
DE (1) | DE69321218T2 (de) |
DK (1) | DK0627002T3 (de) |
ES (1) | ES2121078T3 (de) |
HK (1) | HK1008831A1 (de) |
IL (1) | IL104782A0 (de) |
MX (1) | MX9300913A (de) |
NZ (1) | NZ249677A (de) |
SG (1) | SG52215A1 (de) |
WO (1) | WO1993017106A1 (de) |
ZA (1) | ZA931148B (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG52215A1 (en) * | 1992-02-19 | 1998-09-28 | Schering Corp | Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4 |
EP0604693A1 (de) * | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoklonale Antikörper gegen den menschlichen Interleukin-4-Rezeptor und Hybridomen die diese produzieren |
CA2171336C (en) * | 1993-09-07 | 2011-06-21 | Stephen Dudley Holmes | Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5597710A (en) * | 1994-03-10 | 1997-01-28 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
CA2333147C (en) | 1998-07-13 | 2012-02-07 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
EP1173790A2 (de) * | 1999-03-01 | 2002-01-23 | Boston Innovative Optics, Inc. | Vorrichtung und verfahren zur erhöhung der tiefenschärfe des menschlichen auges |
ES2614260T3 (es) | 2000-05-26 | 2017-05-30 | Immunex Corporation | Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
ES2358730T3 (es) | 2002-07-15 | 2011-05-13 | Board Of Regents, The University Of Texas System | Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer. |
WO2004044161A2 (en) * | 2002-11-06 | 2004-05-27 | Fraunhofer Usa | Expression of foreign sequences in plants using trans-activation system |
US7683238B2 (en) * | 2002-11-12 | 2010-03-23 | iBio, Inc. and Fraunhofer USA, Inc. | Production of pharmaceutically active proteins in sprouted seedlings |
US7692063B2 (en) * | 2002-11-12 | 2010-04-06 | Ibio, Inc. | Production of foreign nucleic acids and polypeptides in sprout systems |
US7276589B2 (en) | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
JP4741242B2 (ja) | 2002-11-26 | 2011-08-03 | アボット バイオセラピューティクス コーポレイション | 新脈管形成を調節するα5β1インテグリンへのキメラ及びヒト化抗体 |
US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US20110223168A1 (en) * | 2002-12-27 | 2011-09-15 | Greg Winter | Ligand that has binding specificity for il-4 and/or il-13 |
ES2531125T3 (es) * | 2003-02-03 | 2015-03-10 | Ibio Inc | Sistema para la expresión de genes en plantas |
EP1625165A2 (de) * | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Integrin alpha5beta1 inhibitoren und deren verwendung zur kontrolle der gewebe-granulation |
WO2005026375A2 (en) | 2003-05-22 | 2005-03-24 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
US7628810B2 (en) * | 2003-05-28 | 2009-12-08 | Acufocus, Inc. | Mask configured to maintain nutrient transport without producing visible diffraction patterns |
US20050046794A1 (en) * | 2003-06-17 | 2005-03-03 | Silvestrini Thomas A. | Method and apparatus for aligning a mask with the visual axis of an eye |
ES2532609T3 (es) * | 2004-02-20 | 2015-03-30 | Ibio, Inc. | Sistemas y métodos para expresión clonales en plantas |
ATE531388T1 (de) * | 2004-03-24 | 2011-11-15 | Abbott Biotherapeutics Corp | Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation |
AR050044A1 (es) | 2004-08-03 | 2006-09-20 | Novartis Ag | Anticuerpo especifico de il-4 |
US7976577B2 (en) | 2005-04-14 | 2011-07-12 | Acufocus, Inc. | Corneal optic formed of degradation resistant polymer |
CA2616859C (en) * | 2005-08-03 | 2015-04-14 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
EA200801515A1 (ru) * | 2006-01-24 | 2009-02-27 | Домантис Лимитед | Лиганды, которые связывают il-4 и/или il-13 |
JP2009526526A (ja) * | 2006-02-13 | 2009-07-23 | フラウンホーファー ユーエスエー, インコーポレイテッド | インフルエンザ抗原、ワクチン組成物、および関連する方法 |
US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
US20080279877A1 (en) * | 2006-02-13 | 2008-11-13 | Fraunhofer U.S.A. Inc. | HPV antigens, vaccine compositions, and related methods |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
WO2009131553A2 (en) | 2006-12-29 | 2009-10-29 | Osteogenex Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
EP2152301A4 (de) * | 2007-04-28 | 2010-07-28 | Fraunhofer Usa Inc | Trypanosomaantigene, impfstoffzusammensetzungen und zugehörige verfahren |
US8404252B2 (en) | 2007-07-11 | 2013-03-26 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
BRPI0813630A2 (pt) * | 2007-07-27 | 2019-09-24 | Facet Biotech Corp | combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e) |
WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
IN2012DN02154A (de) * | 2009-08-13 | 2015-08-07 | Acufocus Inc | |
WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
USD656526S1 (en) | 2009-11-10 | 2012-03-27 | Acufocus, Inc. | Ocular mask |
WO2013009767A2 (en) | 2011-07-12 | 2013-01-17 | Epitomics, Inc. | Facs-based method for obtaining an antibody sequence |
WO2013082545A1 (en) | 2011-12-02 | 2013-06-06 | Acufocus, Inc. | Ocular mask having selective spectral transmission |
WO2014074218A1 (en) | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
US9605078B2 (en) | 2012-11-16 | 2017-03-28 | The Regents Of The University Of California | Pictet-Spengler ligation for protein chemical modification |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
US9204962B2 (en) | 2013-03-13 | 2015-12-08 | Acufocus, Inc. | In situ adjustable optical mask |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US9427922B2 (en) | 2013-03-14 | 2016-08-30 | Acufocus, Inc. | Process for manufacturing an intraocular lens with an embedded mask |
CN103421747B (zh) * | 2013-09-09 | 2015-01-07 | 扬州大学 | 分泌牛il-4单克隆抗体的杂交瘤细胞株、其单克隆抗体及其应用 |
ES2714708T3 (es) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim |
US9493413B2 (en) | 2013-11-27 | 2016-11-15 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
US10124070B2 (en) | 2014-06-06 | 2018-11-13 | Redwood Bioscience, Inc. | Anti-HER2 antibody-maytansine conjugates and methods of use thereof |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
ES2822228T3 (es) | 2014-10-24 | 2021-04-29 | Univ Leland Stanford Junior | Composiciones y métodos para inducir la fagocitosis de células positivas de clase I de CMH y contrarrestar la resistencia a anti-CD47/SIRPA |
US9982057B2 (en) | 2014-11-17 | 2018-05-29 | Pelican Therapeutics, Inc. | Human TNFRSF25 antibody |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
US20190209697A1 (en) | 2015-11-05 | 2019-07-11 | The Regents Of The University Of California | Cells labelled with lipid conjugates and methods of use thereof |
WO2017214547A1 (en) | 2016-06-09 | 2017-12-14 | Pelican Therapeutics, Inc. | Anti-tnfrsf25 antibodies |
US10240581B2 (en) | 2017-02-08 | 2019-03-26 | General Electric Company | System and method for controlling pitch angle of a wind turbine rotor blade |
CN110540590B (zh) * | 2018-05-29 | 2023-08-18 | 康诺亚生物医药科技(成都)有限公司 | 一种自免疫抑制物的开发和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041381A (en) * | 1986-07-03 | 1991-08-20 | Schering Corporation | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same |
IL89489A0 (en) * | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB9105292D0 (en) * | 1991-03-13 | 1991-04-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
SG52215A1 (en) * | 1992-02-19 | 1998-09-28 | Schering Corp | Cloning and expresssion of humanized monoclonal antibodies against human interleukin-4 |
-
1993
- 1993-02-18 SG SG1996000536A patent/SG52215A1/en unknown
- 1993-02-18 WO PCT/US1993/001301 patent/WO1993017106A1/en active IP Right Grant
- 1993-02-18 ES ES93905927T patent/ES2121078T3/es not_active Expired - Lifetime
- 1993-02-18 EP EP93905927A patent/EP0627002B1/de not_active Expired - Lifetime
- 1993-02-18 US US08/290,793 patent/US5863537A/en not_active Expired - Lifetime
- 1993-02-18 AT AT93905927T patent/ATE171472T1/de not_active IP Right Cessation
- 1993-02-18 JP JP5514908A patent/JPH07502901A/ja active Pending
- 1993-02-18 CA CA002130436A patent/CA2130436C/en not_active Expired - Fee Related
- 1993-02-18 DE DE69321218T patent/DE69321218T2/de not_active Expired - Fee Related
- 1993-02-18 IL IL104782A patent/IL104782A0/xx unknown
- 1993-02-18 ZA ZA931148A patent/ZA931148B/xx unknown
- 1993-02-18 DK DK93905927T patent/DK0627002T3/da active
- 1993-02-18 NZ NZ249677A patent/NZ249677A/en unknown
- 1993-02-18 AU AU36662/93A patent/AU684041B2/en not_active Ceased
- 1993-02-18 KR KR1019940702925A patent/KR0158240B1/ko not_active IP Right Cessation
- 1993-02-19 MX MX9300913A patent/MX9300913A/es not_active IP Right Cessation
- 1993-02-19 CN CN93103442A patent/CN1076966A/zh active Pending
-
1995
- 1995-06-06 US US08/469,557 patent/US5770403A/en not_active Expired - Lifetime
-
1998
- 1998-07-29 HK HK98109512A patent/HK1008831A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US5863537A (en) | 1999-01-26 |
DK0627002T3 (da) | 1999-06-14 |
ZA931148B (en) | 1993-08-18 |
DE69321218T2 (de) | 1999-02-18 |
AU684041B2 (en) | 1997-12-04 |
DE69321218D1 (de) | 1998-10-29 |
SG52215A1 (en) | 1998-09-28 |
NZ249677A (en) | 1996-08-27 |
HK1008831A1 (en) | 1999-05-21 |
IL104782A0 (en) | 1993-06-10 |
KR0158240B1 (ko) | 1998-11-16 |
CN1076966A (zh) | 1993-10-06 |
CA2130436C (en) | 2001-04-10 |
EP0627002B1 (de) | 1998-09-23 |
AU3666293A (en) | 1993-09-13 |
WO1993017106A1 (en) | 1993-09-02 |
EP0627002A1 (de) | 1994-12-07 |
MX9300913A (es) | 1994-08-31 |
JPH07502901A (ja) | 1995-03-30 |
ES2121078T3 (es) | 1998-11-16 |
US5770403A (en) | 1998-06-23 |
KR950700414A (ko) | 1995-01-16 |
CA2130436A1 (en) | 1993-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE171472T1 (de) | Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4 | |
DE69322860T2 (de) | Antikörper gegen alpha v beta 3 integrin | |
MY108526A (en) | Monoclonal antibodies against human interleukin-4 and hybridomas producing the same | |
ATE255902T1 (de) | Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten | |
FI960567A (fi) | Monoklonaalinen vasta-aine, joka indusoi apoptoosin | |
DE69633973D1 (de) | Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor | |
ATE185606T1 (de) | Monoklonale antikörper gegen putative hcv-e2/ns1- proteine und verfahren zu ihrer verwendung | |
ATE86121T1 (de) | Monoklonale antikoerper und verfahren zum nachweis von pilzpathogenen. | |
DE69504959D1 (de) | Humanisierte monoklonale antikörper gegen humanes interleukin - 4 | |
DK0802924T3 (da) | Lægemiddel til forlænget immunsuppression og eliminering af tumorceller | |
ATE206621T1 (de) | Il-8 antagonisten zur behandlung von asthma | |
DE59508137D1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
ATE178096T1 (de) | Monoklonale antikörper gegen den hepatitis c- virus und verfahren diese zu benutzen | |
ATE70311T1 (de) | Monoklonale antikoerper gegen menschliche igerezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |